Cannabidiol Dosing Protocol for Epilepsy Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anti-epileptic drugs (AEDs) have slow titration periods, leading to breakthrough seizures and low adherence to treatment plans, which increase healthcare resource use and costs, particularly in patients with treatment-resistant epilepsy (TRE).

Innovation Solution

Administering cannabidiol (CBD) at a starting dose of 5 mg/kg/day with incremental increases of 1-5 mg/kg every 4 to 6 days, allowing patients to reach maintenance doses sooner, thereby reducing breakthrough seizures and improving treatment adherence.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional AEDs are used with slow titration, then safety and tolerability are improved, but titration time is extended and breakthrough seizures increase

Engineering Contradiction:

Improvesafety and tolerabilityVSAvoidtitration time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the dosing parameters by administering CBD at a standardized concentration (100 mg/mL) with specific titration increments (5 mg/kg every 7 days), enabling faster titration to maintenance doses while maintaining safety through controlled parameter adjustments

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses CBD as an intermediary substance that bridges the gap between slow titration safety requirements and fast titration time needs, achieving both goals through its specific pharmacological properties and standardized formulation

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-generated harmful factors

If slow titration is used, then adverse events are minimized, but adherence to treatment plan decreases and healthcare resource use increases

Engineering Contradiction:

Improveadverse eventsVSAvoidadherence to treatment plan

Core Design Contradiction:

Object-generated harmful factorsVSProductivity

Solution Approach 1:

The patent segments the titration process into defined phases with specific dose increments (5 mg/kg every 7 days), making the treatment plan more structured and manageable, which improves adherence while controlling adverse events through systematic progression

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent incorporates monitoring and assessment mechanisms to evaluate patient response and tolerance during titration, allowing real-time adjustments that maintain safety while keeping patients engaged and adherent to the treatment plan

Inventive Principle:

Principle #23Feedback

3Loss of time

If rapid titration is used, then titration time is shortened, but breakthrough seizures may increase during the transition

Engineering Contradiction:

Improvetitration timeVSAvoidbreakthrough seizures

Core Design Contradiction:

Loss of timeVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by pre-establishing the titration schedule with 5 mg/kg increments every 7 days before starting treatment, and by administering a loading dose strategy that proactively ensures therapeutic levels are reached quickly while minimizing breakthrough seizures through planned dose escalation

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20240016819A1Cannabinoids for use in the treatment of epilepsy

Publication Date: 2024.01.18 GW RES LTD

AI summary

The present invention relates to a method of treating seizures using cannabidiol (CBD), which significantly shortens the dose titration period. This results inpatients receiving maintenance doses sooner after initiating treatment, which reduces the occurrence of breakthrough seizures and improves adherence to treatment.